Jacqui Rowbottom

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Ekaterina Trishkina, Mikhail Dvorkin et al. · The Lancet · 2016 · 602 citations · Full text

Medicine, Oncology, Pharmacology +14

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M. Oza, David Cibula, Ana Oaknin Benzaquen et al. · The Lancet Oncology · 2014 · 544 citations

Medicine, Gynecology, Oncology +14

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Ronald B. Natale, Sumitra Thongprasert, F. Anthony Greco et al. · Journal of Clinical Oncology · 2011 · 296 citations

Medicine, Oncology, Pharmacology +9

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

Yung‐Jue Bang, Seock‐Ah Im, Keun‐Wook Lee et al. · Journal of Clinical Oncology · 2015 · 294 citations · Full text

Medicine, Oncology, Pharmacology +15

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

Kathy D. Miller, José Trigo, Catherine Wheeler et al. · Clinical Cancer Research · 2005 · 197 citations

Medicine, Pharmacology, Pharmacotherapy +17